Qiagen (NYSE:QGEN) Price Target Lowered to $48.00 at UBS Group

Qiagen (NYSE:QGEN) had its target price decreased by UBS Group from $50.00 to $48.00 in a research note issued to investors on Friday,Benzinga reports. UBS Group currently has a neutral rating on the stock.

A number of other research firms also recently commented on QGEN. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective on the stock. in a research note on Thursday, October 17th. Morgan Stanley reissued an “equal weight” rating and issued a $46.67 price target (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $52.50 target price (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Qiagen currently has an average rating of “Moderate Buy” and a consensus target price of $49.84.

Qiagen Trading Down 2.6 %

NYSE:QGEN opened at $41.34 on Friday. The stock has a market cap of $9.17 billion, a price-to-earnings ratio of 115.09, a PEG ratio of 3.29 and a beta of 0.36. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a 1 year low of $40.15 and a 1 year high of $49.30. The business has a fifty day moving average of $43.80 and a 200-day moving average of $43.25.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.97%. Equities analysts predict that Qiagen will post 2.28 earnings per share for the current year.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently modified their holdings of the business. Sanctuary Advisors LLC acquired a new stake in Qiagen during the 2nd quarter worth about $647,000. Park Avenue Securities LLC acquired a new stake in shares of Qiagen during the third quarter worth approximately $304,000. GAMMA Investing LLC grew its position in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares in the last quarter. CWM LLC increased its stake in Qiagen by 11.5% in the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock valued at $127,000 after buying an additional 287 shares during the period. Finally, Creative Planning lifted its position in Qiagen by 12.7% in the 3rd quarter. Creative Planning now owns 40,571 shares of the company’s stock worth $1,849,000 after buying an additional 4,561 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.